Serum Institute of India COVID-19 Vaccine advances to trial for phase-III on 1500 Indian patients

Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate

Serum institute has completed phase II-B3 trails and will commence phase-III trail after clearances. The third phase trail will be tested on 1500 patients at 14 locations. Balram Bhargava, Director general of the Indian Council of Medical Research, said, “The testing will not be random and will only be tested on those who show COVID-19 symptoms.”

The Oxford vaccine is in the most advanced stages of being developed, and is predicted release in the next two months.

Zycov D and Bharat have cleared phase 1 trails on humans. Zydus Cadila says it may be able to launch the vaccine by next year. Researchers continue efforts on releasing COVID vaccines.

RELATED ARTICLESMORE FROM AUTHOR